Agilent Technologies Reports 6% Revenue Growth to $1.668 Billion in Q2 2025

Agilent Technologies, Inc. reported a net revenue of $1.668 billion for the three months ended April 30, 2025, marking a 6% increase from $1.573 billion in the same period last year. For the six months ended April 30, 2025, revenue rose 4% to $3.349 billion compared to $3.231 billion in the prior year. The growth was driven primarily by the Life Sciences and Diagnostics Markets segment, which saw an 8% increase in revenue for the quarter, and a 6% increase for the half-year. However, the Applied Markets segment experienced a slight decline in revenue, decreasing by 1% and 3% for the respective periods.

Net income for the second quarter was $215 million, down from $308 million a year earlier, while net income for the first half of 2025 was $533 million, compared to $656 million in the same period of 2024. The decrease in profitability was attributed to higher costs, including increased selling, general, and administrative expenses, which rose by 19% in the second quarter. The operating margin also declined to 18% from 23% in the previous year, reflecting pressures from product mix and increased operational costs.

Agilent's organizational structure underwent a significant change in November 2024, resulting in the formation of three new segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. This restructuring aims to enhance customer focus and operational efficiency. The company also reported a headcount increase to approximately 18,000 employees as of April 30, 2025, up from 17,600 a year earlier, indicating ongoing investments in human resources to support growth.

In terms of cash flow, Agilent generated $652 million from operations in the first half of 2025, a decrease from $818 million in the same period last year. The company’s cash and cash equivalents increased to $1.486 billion from $1.329 billion at the end of October 2024. Agilent continued its share repurchase program, buying back $255 million worth of stock in the first half of 2025, and declared a quarterly dividend of $0.248 per share, reflecting a commitment to returning value to shareholders.

Looking ahead, Agilent anticipates challenges from recent tariff changes that may impact costs in the latter half of fiscal 2025. However, the company remains optimistic about long-term growth opportunities across its key markets, particularly in life sciences and diagnostics, and plans to continue investing in research and development to enhance its product offerings.